Drug intelligence / Profile preview

S-1 + oxaliplatin + penpulimab

Development stage: Unknown
Lead developer: Kangfang Sainuo Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

S-1 + oxaliplatin + penpulimab is a combination therapy consisting of three components: S-1 (an oral fluoropyrimidine), oxaliplatin (a platinum-based chemotherapy agent), and penpulimab (an anti-PD-1 monoclonal antibody). Penpulimab is a novel PD-1 inhibitor with no Fc gamma receptor (FcγR) binding activity, which theoretically reduces immune-related adverse events while maintaining efficacy. This combination likely leverages both cytotoxic chemotherapy mechanisms and immune checkpoint inhibition to treat cancer.

Targets

TS (Thymidylate synthase)DNAPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on S-1 + oxaliplatin + penpulimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-1 + oxaliplatin + penpulimab.

Explore the full profile